Oxaliplatin¿¡ ÀÇÇÑ ¾Èµ¶¼ºÀÇ 1¿¹
A Case of Oxaliplatin-Related Ocular Toxicity
´ëÇѾȰúÇÐȸÁö 2014³â 55±Ç 1È£ p.143 ~ p.148
¹ÚÇѼ®(Park Han-Seok) - ¼º±Õ°ü´ëÇб³ Àǰú´ëÇÐ °ºÏ»ï¼ºº´¿ø ¾È°úÇб³½Ç
±è¾çÀç(Kim Yang-Jae) - ¼º±Õ°ü´ëÇб³ Àǰú´ëÇÐ °ºÏ»ï¼ºº´¿ø ¾È°úÇб³½Ç
¼Û¼öÁ¤(Song Su-Jeong) - ¼º±Õ°ü´ëÇб³ Àǰú´ëÇÐ °ºÏ»ï¼ºº´¿ø ¾È°úÇб³½Ç
¹èÁ¤ÈÆ(Bae Jeong-Hun) - ¼º±Õ°ü´ëÇб³ Àǰú´ëÇÐ °ºÏ»ï¼ºº´¿ø ¾È°úÇб³½Ç
Abstract
¸ñÀû: Oxaliplatin (Eloxatin¢ç) Åõ¿© ÈÄ ¹ß»ýÇÑ ¾Èµ¶¼ºÀÇ ¿¹¸¦ °æÇèÇÏ¿´±â¿¡ º¸°íÇϰíÀÚ ÇÑ´Ù.
Áõ·Ê¿ä¾à: 43¼¼ ¿©ÀÚ È¯ÀÚ°¡ 1´Þ ÀüºÎÅÍ ¹ß»ýÇÑ ¾ç¾ÈÀÇ ½Ã¾ß Àå¾Ö¿Í ¾îµÎ¿ö º¸ÀÌ´Â Áõ»óÀ¸·Î ÀǷڵǾú´Ù. ÁøÇ༺ À§¾Ï 4±â·Î Oxaliplatin À» Æ÷ÇÔÇÑ XELOX 1Â÷ Ç×¾ÏÄ¡·á ÈÄ »ó±â Áõ»óÀÌ ¹ß»ýÇÏ¿´À¸¸ç, ½Ã¾ß °Ë»ç»ó ¾ç¾ÈÀÇ ÁÖº¯ºÎ ½Ã¾ß Àå¾Ö°¡ °üÂûµÇ¾ú°í, ¸Á¸·ÀüÀ§µµ °Ë»ç»ó Àü¹ÝÀûÀ¸·Î ½ÉÇÑ ÁøÆø°¨¼Ò°¡ ÀÖ¾ú´Ù. Oxaliplatin¿¡ ÀÇÇÑ µ¶¼º ¹ÝÀÀÀÌ ÀǽɵǾî 2Â÷ Ç×¾ÏÄ¡·á Áß OxaliplatinÀ» Áß´ÜÇÏ¿´°í, 1´Þ µÚ ȯÀÚ ÀÇ Áõ»óÀº È£ÀüµÇ¾úÀ¸¸ç, ¸Á¸·ÀüÀ§µµ °Ë»çÀÇ ÀÌ»óµµ Á¡Â÷ ȸº¹µÇ¾úÁö¸¸ 3´Þ ÈÄ¿¡µµ Áö¼ÓÀûÀÎ ÁøÆø°¨¼Ò°¡ °üÂûµÇ¾ú´Ù.
°á·Ð: Platinum°è Ç×¾ÏÁ¦ÀÎ OxaliplatinÀº ¸Á¸·ÀÇ ±¤¼ö¿ëü³ª ½Ã½Å°æÀÇ ¼Õ»óÀ» À¯¹ßÇÒ ¼ö ÀÖ¾î »ç¿ë½Ã ÁÖÀÇ ±íÀº °üÂûÀÌ ÇÊ¿äÇϸç, ÀÌ·¯ ÇÑ µ¶¼ºÀº Á¶±â Áø´Ü°ú ¾à¹°ÀÇ Áß´ÜÀ¸·Î ½É°¢Çϰí, ºñ°¡¿ªÀûÀÎ ¼Õ»óÀ» ¿¹¹æÇÒ ¼ö ÀÖ´Ù.
Purpose: To report a case of oxaliplatin (Eloxatin¢ç)-related ocular toxicity in a patient with advanced stomach cancer.
Case summary: A 43-year-old female with advanced stomach cancer experienced visual symptoms during the treatment with oxaliplatin on a XELOX schedule (a combination of oxaliplatin and capecitabine). After 1 cycle of chemotherapy, she complained of blurred vision and visual field defects in both eyes. Visual field tests showed a bilateral concentric field defect and the electroretinogram revealed a marked reduction of responses in both eyes. On the second cycle of chemotherapy, oxaliplatin was discontinued due to suspicious ocular toxicity. Her visual symptoms improved and visual field test showed normal results 1 month after oxaliplatin discontinuation. However, 3 months after oxaliplatin discontinuation, electroretinogram remained abnormal despite the progressive improvement.
Conclusions: Platinum-based antineoplastic agents such as oxaliplatin should be administered with caution because oxaliplatin can cause damage to the retinal photoreceptors and the optic nerve. Early detection of ocular toxicity and discontinuation of oxaliplatin therapy could prevent severe and irreversible visual loss.
Ű¿öµå
Electroretinogram, Ocular toxicity, Oxaliplatin, XELOX
KMID :
0360220140550010143
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)